Media stories about Utah Medical Products (NASDAQ:UTMD) have trended somewhat positive on Wednesday, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Utah Medical Products earned a news sentiment score of 0.05 on Accern’s scale. Accern also assigned press coverage about the medical instruments supplier an impact score of 44.9664166832102 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of UTMD stock traded up $0.55 during midday trading on Wednesday, hitting $95.50. The company had a trading volume of 1,903 shares, compared to its average volume of 15,395. The company has a market cap of $348.25, a P/E ratio of 23.94 and a beta of 0.77. Utah Medical Products has a 1-year low of $58.50 and a 1-year high of $96.55.
Utah Medical Products (NASDAQ:UTMD) last announced its quarterly earnings results on Tuesday, January 30th. The medical instruments supplier reported $0.95 earnings per share (EPS) for the quarter. The business had revenue of $10.20 million for the quarter. Utah Medical Products had a return on equity of 18.85% and a net margin of 20.54%.
Separately, BidaskClub downgraded Utah Medical Products from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th.
In other Utah Medical Products news, CEO Kevin L. Cornwell sold 1,095 shares of Utah Medical Products stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $91.01, for a total transaction of $99,655.95. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Ernst G. Hoyer sold 1,529 shares of Utah Medical Products stock in a transaction on Friday, February 9th. The shares were sold at an average price of $88.08, for a total value of $134,674.32. The disclosure for this sale can be found here. Insiders have sold a total of 16,169 shares of company stock worth $1,466,903 in the last ninety days. 8.80% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Utah Medical Products (NASDAQ:UTMD) Stock Price” was reported by BBNS and is the property of of BBNS. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://baseballnewssource.com/2018/03/21/utah-medical-products-utmd-given-news-impact-rating-of-0-05/2028358.html.
Utah Medical Products Company Profile
Utah Medical Products, Inc (UTMD) is engaged in the business of producing medical devices that are disposable and for hospital use. The Company’s product categories include labor and delivery/obstetrics, including fetal monitoring accessories, Vacuum-Assisted Delivery Systems (VAD), and other labor and delivery tools; neonatal intensive care, including DISPOSA-HOOD, DELTRAN PLUS and GESCO; gynecology/urology/electrosurgery, including LETZ System, FINESSE+ Generator, EPITOME, PATHFINDER PLUS, HOLMIUM LASER FIBRES, LIBERTY System, ENDOCURETTE, TVUS/HSG-Cath and LUMIN, and blood pressure monitoring, including DELTRAN Disposable Pressure Transducer (DPT), and pressure monitoring accessories, components and other molded parts.
Receive News & Ratings for Utah Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Utah Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.